- Home
- IDYA vs GOF Comparison
IDYA vs GOF Comparison
Compare IDYA & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- GOF
- Stock Information
- Founded
- IDYA 2015
- GOF 2006
- Country
- IDYA United States
- GOF United States
- Employees
- IDYA N/A
- GOF N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- IDYA Health Care
- GOF Finance
- Exchange
- IDYA Nasdaq
- GOF Nasdaq
- Market Cap
- IDYA 2.3B
- GOF 2.7B
- IPO Year
- IDYA 2019
- GOF N/A
- Fundamental
- Price
- IDYA $24.44
- GOF $14.90
- Analyst Decision
- IDYA Buy
- GOF
- Analyst Count
- IDYA 14
- GOF 0
- Target Price
- IDYA $47.75
- GOF N/A
- AVG Volume (30 Days)
- IDYA 1.2M
- GOF 789.2K
- Earning Date
- IDYA 11-03-2025
- GOF 01-01-0001
- Dividend Yield
- IDYA N/A
- GOF 15.42%
- EPS Growth
- IDYA N/A
- GOF N/A
- EPS
- IDYA N/A
- GOF N/A
- Revenue
- IDYA $7,000,000.00
- GOF N/A
- Revenue This Year
- IDYA $62.30
- GOF N/A
- Revenue Next Year
- IDYA $285.58
- GOF N/A
- P/E Ratio
- IDYA N/A
- GOF N/A
- Revenue Growth
- IDYA N/A
- GOF N/A
- 52 Week Low
- IDYA $13.45
- GOF $10.96
- 52 Week High
- IDYA $37.19
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- IDYA 49.04
- GOF 44.22
- Support Level
- IDYA $24.24
- GOF $14.95
- Resistance Level
- IDYA $25.49
- GOF $15.11
- Average True Range (ATR)
- IDYA 1.35
- GOF 0.09
- MACD
- IDYA -0.15
- GOF -0.02
- Stochastic Oscillator
- IDYA 27.13
- GOF 18.75
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.